@article{oai:repo.qst.go.jp:00049220,
 author = {Hanadate, Sayaka and Yoshii, Yukie and Koushin, Washiyama and Yoshimoto, Mitsuyoshi and Tomoo, Yamamura and Makoto, Watanabe and Matsumoto, Hiroki and Igarashi, Mineko and Higashi, Tatsuya and Hanadate, Sayaka and Yoshii, Yukie and Koushin, Washiyama and Yoshimoto, Mitsuyoshi and Matsumoto, Hiroki and Igarashi, Mineko and Higashi, Tatsuya},
 issue = {2},
 journal = {International Journal of Sciences:Basic and Applied Research},
 month = {Oct},
 note = {Targeted alpha therapy with 223RaCl2 is used to treat skeletal metastases of hormone-refractory prostate cancer. The intravenous injection of 223RaCl2 causes gastrointestinal disorders such as nausea, abdominal discomfort, and diarrhea as frequent clinical adverse events caused by radiation. BaSO4 is known to display Ra2+ ion uptake in its structure and is clinically used as a contrast agent for X-ray imaging following oral administration. Here, we investigated the feasibility of a method to reduce 223Ra retention in the large intestine with BaSO4 by biodistribution studies in mice. 223RaCl2 biodistribution was examined in ddY mice after intravenous administration (10 kBq/mouse).},
 pages = {95--105},
 title = {Reduction of 223Ra retention in the large intestine during targeted alpha therapy with 223RaCl2 by oral BaSO4 administration in mice},
 volume = {42},
 year = {2018}
}